109 related articles for article (PubMed ID: 23468257)
1. New prognostic factors in breast cancer.
Adam Maciejczyk A
Adv Clin Exp Med; 2013; 22(1):5-15. PubMed ID: 23468257
[TBL] [Abstract][Full Text] [Related]
2. Prognostic significance of serum Her2/neu, BCL2, CA15-3 and CEA in breast cancer patients: a short follow-up.
Samy N; Ragab HM; El Maksoud NA; Shaalan M
Cancer Biomark; 2010; 6(2):63-72. PubMed ID: 20571232
[TBL] [Abstract][Full Text] [Related]
3. Prognostic value of NDRG1 and SPARC protein expression in breast cancer patients.
Nagai MA; Gerhard R; Fregnani JH; Nonogaki S; Rierger RB; Netto MM; Soares FA
Breast Cancer Res Treat; 2011 Feb; 126(1):1-14. PubMed ID: 20369286
[TBL] [Abstract][Full Text] [Related]
4. [Claudins as prognostic factors of breast cancer].
Szász MA
Magy Onkol; 2012 Sep; 56(3):209-12. PubMed ID: 23139925
[TBL] [Abstract][Full Text] [Related]
5. Staging of women with breast cancer after introduction of sentinel node guided axillary dissection.
Tvedskov TF
Dan Med J; 2012 Jul; 59(7):B4475. PubMed ID: 22759850
[TBL] [Abstract][Full Text] [Related]
6. New generation of molecular prognostic and predictive tests for breast cancer.
Pusztai L; Cristofanilli M; Paik S
Semin Oncol; 2007 Apr; 34(2 Suppl 3):S10-6. PubMed ID: 17512431
[TBL] [Abstract][Full Text] [Related]
7. Identification of subtypes in human epidermal growth factor receptor 2--positive breast cancer reveals a gene signature prognostic of outcome.
Staaf J; Ringnér M; Vallon-Christersson J; Jönsson G; Bendahl PO; Holm K; Arason A; Gunnarsson H; Hegardt C; Agnarsson BA; Luts L; Grabau D; Fernö M; Malmström PO; Johannsson OT; Loman N; Barkardottir RB; Borg A
J Clin Oncol; 2010 Apr; 28(11):1813-20. PubMed ID: 20231686
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of prognostic parameters of E-cadherin status in breast cancer treatment.
Brzozowska A; Sodolski T; Duma D; Mazurkiewicz T; Mazurkiewicz M
Ann Agric Environ Med; 2012; 19(3):541-6. PubMed ID: 23020053
[TBL] [Abstract][Full Text] [Related]
9. Relationship between the expression of various markers and prognostic factors in breast cancer.
Anim JT; John B; Abdulsathar S SA; Prasad A; Saji T; Akhtar N; Ali V; Al-Saleh M
Acta Histochem; 2005; 107(2):87-93. PubMed ID: 15950051
[TBL] [Abstract][Full Text] [Related]
10. Cyclin E as a prognostic and predictive marker in breast cancer.
Hunt KK; Keyomarsi K
Semin Cancer Biol; 2005 Aug; 15(4):319-26. PubMed ID: 16043362
[TBL] [Abstract][Full Text] [Related]
11. Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancer.
Martín M; Rodríguez-Lescure A; Ruiz A; Alba E; Calvo L; Ruiz-Borrego M; Munárriz B; Rodríguez CA; Crespo C; de Alava E; López García-Asenjo JA; Guitián MD; Almenar S; González-Palacios JF; Vera F; Palacios J; Ramos M; Gracia Marco JM; Lluch A; Alvarez I; Seguí MA; Mayordomo JI; Antón A; Baena JM; Plazaola A; Modolell A; Pelegrí A; Mel JR; Aranda E; Adrover E; Alvarez JV; García Puche JL; Sánchez-Rovira P; Gonzalez S; López-Vega JM;
J Natl Cancer Inst; 2008 Jun; 100(11):805-14. PubMed ID: 18505968
[TBL] [Abstract][Full Text] [Related]
12. [Assessment of prognostic factors in breast cancer].
Neagu A; Muscă S; Slătineanu S; Pricop M
Rev Med Chir Soc Med Nat Iasi; 2005; 109(2):276-80. PubMed ID: 16607785
[TBL] [Abstract][Full Text] [Related]
13. Alpha- and beta-adrenergic receptor (AR) protein expression is associated with poor clinical outcome in breast cancer: an immunohistochemical study.
Powe DG; Voss MJ; Habashy HO; Zänker KS; Green AR; Ellis IO; Entschladen F
Breast Cancer Res Treat; 2011 Nov; 130(2):457-63. PubMed ID: 21298476
[TBL] [Abstract][Full Text] [Related]
14. Expression level of insulin-like growth factor binding protein 5 mRNA is a prognostic factor for breast cancer.
Li X; Cao X; Li X; Zhang W; Feng Y
Cancer Sci; 2007 Oct; 98(10):1592-6. PubMed ID: 17651454
[TBL] [Abstract][Full Text] [Related]
15. LEA-135 expression: its association with a lower risk of recurrence and increased overall survival of patients with lymph node-positive primary invasive breast cancer.
Saha B; Zhang N; Naritoku WY; Tsao-Wei DD; Groshen SL; Carlsson G; Larsson L; Gustavsson B; Chaiwun B; Taylor CR; Imam SA
Anticancer Res; 2004; 24(4):2391-400. PubMed ID: 15330189
[TBL] [Abstract][Full Text] [Related]
16. The role of hormonal therapy in the management of hormonal-receptor-positive breast cancer with co-expression of HER2.
Prat A; Baselga J
Nat Clin Pract Oncol; 2008 Sep; 5(9):531-42. PubMed ID: 18607391
[TBL] [Abstract][Full Text] [Related]
17. Prognostic molecular markers in women aged 35 years or younger with breast cancer: is there a difference from the older patients?
Lin CH; Lu YS; Huang CS; Kuo KT; Wang CC; You SL; Lin PH; Chang DY; Kuo WH; Chang KJ; Cheng AL
J Clin Pathol; 2011 Sep; 64(9):781-7. PubMed ID: 21642658
[TBL] [Abstract][Full Text] [Related]
18. P-cadherin as prognostic factor for loco-regional relapse in breast cancer.
Faria G; Cardoso MJ; Martins D; Bettencourt H; Amendoeira I; Schimitt F
Acta Med Port; 2012; 25(2):97-105. PubMed ID: 22985920
[TBL] [Abstract][Full Text] [Related]
19. Tumour markers CEA and CA 15-3 as Prognostic factors in breast cancer--univariate and multivariate analysis.
Ebeling FC; Schmitt UM; Untch M; Nagel D; Fateh-Moghadam A; Stieber P; Seidel D
Anticancer Res; 1999; 19(4A):2545-50. PubMed ID: 10470192
[TBL] [Abstract][Full Text] [Related]
20. [Proliferation index and its prognostic value in invasive ductal breast carcinoma].
Falco M
Ann Acad Med Stetin; 2009; 55(1):22-30. PubMed ID: 20349588
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]